ICD-10 M32.14 is officially defined as "Glomerular disease in systemic lupus erythematosus." code M32.14 is referenced in 7 tracked payer policy changes from Blue Cross Blue Shield of North Dakota, Excellus BlueCross BlueShield, and 3 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code M32.14 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Blue Cross Blue Shield of North Dakota's August 2026 pharmacy update covers Medicaid Expansion medical drug prior authorization policies, with new policies and coding changes effective October 1, 2026. The most important billing change is the new HCPCS codes that replace older codes, such as Q5172 for Filkri and J9362 for Yondelis, plus added diagnosis codes for several drugs; the commercial pharmacy policies were reviewed with no changes listed.
Excellus BlueCross BlueShield policy 07.02.01 covers pancreas transplant alone for insulin-dependent diabetes that is difficult to manage, when the patient has had frequent, acute, and severe metabolic complications requiring medical attention, consistent failure of insulin-based management, and no advanced kidney disease (stage IV or V). Pancreas transplant after kidney transplant and simultaneous pancreas-kidney transplant are considered medically appropriate under listed criteria. A second pancreas transplant after a failed primary transplant is considered medically appropriate for individuals who still meet transplant criteria. Autologous islet cell transplantation is considered medically appropriate as an adjunct to total or near-total pancreatectomy in chronic pancreatitis. Allogeneic islet cell transplantation with FDA-approved donislecel-jujn (Lantidra) is considered investigational for type 1 diabetes. This version is effective March 19, 2026.
Commercial prior authorization medical drug policies have revisions effective Feb. 10, 2026, including new indications such as Epkinly in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma, Gazyva for active lupus nephritis, Darzalex SQ for high-risk smoldering multiple myeloma, and Bevacizumab for respiratory papillomatosis. Commercial post service claim edit policies for Botox, Dysport, Daxxify, Myobloc, Xeomin, Asparlas, and Besponsa have revisions effective Jan. 1, 2026, with multiple sclerosis coverage moving from G35 to G35.A through G35.D. Vyepti now covers chronic migraine with ICD-10 codes G43.E01, G43.E09, G43.E11, and G43.E19, and the Infugem policy is being retired because the manufacturer discontinued the product.
Aetna considers obinutuzumab (Gazyva) medically necessary for commercial medical plans for these indications: chronic lymphocytic leukemia or small lymphocytic lymphoma, as a single agent or in combination with acalabrutinib, venetoclax, bendamustine, or chlorambucil, or with high-dose methylprednisolone for del(17p)/TP53 mutation disease; follicular lymphoma for up to 30 months total; extranodal, splenic and nodal marginal zone lymphoma; histologic transformation of indolent lymphomas and several high-grade B-cell lymphomas, Burkitt lymphoma, HIV-related B-cell lymphomas, post-transplant lymphoproliferative disorders and Castleman disease; mantle cell lymphoma with TP53 mutation; hairy cell leukemia in combination with vemurafenib for members who cannot tolerate purine analogs; and active lupus nephritis in members 18 years of age or older. For several lymphoma indications, use as a substitute for rituximab is covered when the member has intolerance or rare complications from rituximab, such as mucocutaneous reactions. Continuation of therapy is covered when there is no evidence of unacceptable toxicity or disease progression, and for lupus nephritis when the member achieves or maintains a positive clinical response. Re-challenge with the same anti-CD20 monoclonal antibody is not recommended. Aetna considers all other indications experimental, investigational or unproven, including acute lymphoblastic leukemia, B-cell prolymphocytic leukemia, anti-MAG demyelinating neuropathy, immune thrombotic thrombocytopenic purpura, lymphoma of the cervix, nephrotic syndrome, rheumatoid arthritis, systemic lupus erythematosus, Waldenstrom macroglobulinemia, and the combination with pixantrone for relapsed aggressive lymphoma. The available dose is a 1,000 mg/40 mL single-dose vial for intravenous infusion only, and the policy states that it is not to be given as an intravenous push or bolus.
Benlysta (belimumab) requires prior authorization for active systemic lupus erythematosus (SLE) and active lupus nephritis (LN). Lupkynis (voclosporin) and Saphnelo (anifrolumab-fnia) are considered not medically necessary because other formulary alternatives are covered by the plan for these conditions. The most recent review, dated 02/24/2026, revised the medically necessary criteria for members with active SLE without active lupus nephritis.
Benlysta (belimumab) may be considered medically necessary for members with active systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN) when the listed criteria are met. Saphnelo (anifrolumab-fnia) is considered not medically necessary because other formulary alternatives are covered by the Plan for treatment of active SLE. The most recent review, dated 02/24/2026, revised the medically necessary criteria for individuals with active SLE without active lupus nephritis.
Independence Blue Cross reissued Medicare Advantage Policy MA08.057d on 07/22/2026 to communicate its continuing position on belimumab (Benlysta) for intravenous use in systemic lupus erythematosus and lupus nephritis. A guideline restriction on subcutaneous dosing for pediatric patients was removed to align with current FDA labeling. Coverage criteria for SLE and lupus nephritis remain unchanged for patients age 5 and older meeting specified clinical requirements.
Watch M32.14
Get one email when a payer policy names M32.14, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.